Becton Dickinson/Clontech Laboratories
This article was originally published in The Gray Sheet
Executive Summary
BD expects to complete its acquisition of molecular biology research products maker Clontech by Aug. 31. Under a revision of their April 28 merger agreement (1"The Gray Sheet" May 3, p. 13), the deal will now be for $200 mil. in cash instead of stock